SCHEMBL12763540

SCHEMBL12763540

COc1ccccc1-c1c[nH]c2ncc(-c3ccc(C(N)=O)cc3)cc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 2/20 0.70
ABL1 P00519 2/20 0.67
MAP4K1 Q92918 1/20 0.66
CAMKK2 Q96RR4 6/20 0.66
SGK1 O00141 3/20 0.62
KIT P10721 5/20 0.61
AXL P30530 3/20 0.58
INSR P06213 2/20 0.58
MAPK8 P45983 2/20 0.58
DYRK1A Q13627 2/20 0.58
CDC7 O00311 1/20 0.58
PLK4 O00444 1/20 0.58
CHEK1 O14757 1/20 0.58
AURKA O14965 1/20 0.58
MAPK13 O15264 1/20 0.58
PDPK1 O15530 1/20 0.58
DYRK3 O43781 1/20 0.58
ROCK2 O75116 1/20 0.58
RPS6KA5 O75582 1/20 0.58
PRKD3 O94806 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12762863 0.91 ABL1 (0.78) MAP3K11ABL1MAP4K1CAMKK2SGK1
SCHEMBL13342349 0.88 ABL1 (0.83) MAP3K11ABL1MAP4K1CAMKK2SGK1
SCHEMBL12762883 0.86 MAP4K1 (0.69) MAP3K11ABL1MAP4K1CAMKK2KIT
SCHEMBL13341945 0.85 KIT (0.73) MAP3K11ABL1MAP4K1KITDYRK1A
SCHEMBL12762898 0.85 DYRK1A (0.66) MAP3K11ABL1MAP4K1KITDYRK1A
SCHEMBL8321166 0.85 KIT (0.73) MAP3K11ABL1MAP4K1CAMKK2SGK1
SCHEMBL724275 0.85 MAP3K11 (0.86) MAP3K11CAMKK2KITDYRK1ANTRK1
SCHEMBL12763537 0.84 AAK1 (0.80) KITDYRK1ANTRK1AAK1
SCHEMBL12763543 0.84 KIT (0.72) MAP3K11ABL1MAP4K1KITDYRK1A
SCHEMBL12572915 0.83 AXL (0.82) MAP3K11ABL1CAMKK2SGK1AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7906648-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2011-03-15 US disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
US-20090306056-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2009-12-10 US disclosed
US-7601839-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS INC. (US) 2009-10-13 US disclosed
US-7582637-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
US-20090005378-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 US disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed
US-20080221119-A1 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-09-11 US disclosed
US-7361763-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 US disclosed
US-7361764-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2008-04-22 US disclosed
WO-2007106236-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2007-09-20 WO disclosed
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine SGX PHARMACEUTICALS, INC. (US) 2007-02-22 US disclosed
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine SGX PHARMACEUTICALS, INC. (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306056-A1 PYRROLO-PYRIDINE KINASE MODULATORS MAP3K20, MAP4K2, MAP3K19 MAP3K11 19/4885ABL1 235/4885MAP4K1 6/4885
US-20080221119-A1 PYRROLO-PYRIDINE KINASE MODULATORS MAP3K20, MAP4K2, MAP3K19 MAP3K11 19/4885ABL1 235/4885MAP4K1 6/4885
US-20090005378-A1 PYRROLO-PYRIDINE KINASE MODULATORS MAP3K20, MAP4K2, MAP3K19 MAP3K11 19/4885ABL1 235/4885MAP4K1 6/4885
US-20070043068-A1 to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine MAP3K20, MAP4K2, MAP3K6 MAP3K11 21/4885ABL1 96/4885MAP4K1 14/4885
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS MAP4K2, PDXK, MAP4K1 MAP3K11 26/4885ABL1 348/4885MAP4K1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.